{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:57:31Z","timestamp":1787237851081,"version":"build-2736575974"},"reference-count":76,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"Chan Zuckerberg Biohub Physician Scientist Scholar Award, NIH NIDDK LRP Award","doi-asserted-by":"publisher","award":["2L30 DK126220"],"award-info":[{"award-number":["2L30 DK126220"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"Chan Zuckerberg Biohub Physician Scientist Scholar Award, NIH NIDDK LRP Award","doi-asserted-by":"publisher","award":["2021091"],"award-info":[{"award-number":["2021091"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Doris Duke Physician Scientist Fellowship Award","award":["2L30 DK126220"],"award-info":[{"award-number":["2L30 DK126220"]}]},{"name":"Doris Duke Physician Scientist Fellowship Award","award":["2021091"],"award-info":[{"award-number":["2021091"]}]},{"name":"Stanford MCHRI Pediatric IBD and Celiac Disease Research Award","award":["2L30 DK126220"],"award-info":[{"award-number":["2L30 DK126220"]}]},{"name":"Stanford MCHRI Pediatric IBD and Celiac Disease Research Award","award":["2021091"],"award-info":[{"award-number":["2021091"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Colorectal cancer is a known complication of chronic inflammation of the colon (\u201ccolitis-associated colon cancer\u201d). Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract. Patients with IBD are at increased risk of colon cancer compared to the general population. Kinase signaling pathways play critical roles in both the inflammation and regulating cellular processes such as proliferation and survival that contribute to cancer development. Here we review the interplay of kinase signaling pathways (mitogen-activated protein kinases, cyclin-dependent kinases, autophagy-activated kinases, JAK-STAT, and other kinases) and their effects on colitis-associated colon cancer. We also discuss the role of JAK-STAT signaling in the pathogenesis of IBD and the therapeutic landscape of JAK inhibitors for the treatment of IBD.<\/jats:p>","DOI":"10.3390\/biom13111620","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T08:15:56Z","timestamp":1699258556000},"page":"1620","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Kinase Signaling in Colitis-Associated Colon Cancer and Inflammatory Bowel Disease"],"prefix":"10.3390","volume":"13","author":[{"given":"Michelle","family":"Temby","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305-5101, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa L.","family":"Boye","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Medical Section, Herlev Hospital, University of Copenhagen, 2730 Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Hoang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305-5101, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4612-8635","authenticated-orcid":false,"given":"Ole H.","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Medical Section, Herlev Hospital, University of Copenhagen, 2730 Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6037-2883","authenticated-orcid":false,"given":"John","family":"Gubatan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305-5101, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1053\/j.gastro.2019.07.055","article-title":"Epidemiology and Mechanisms of the Increasing Incidence of Colon and Rectal Cancers in Young Adults","volume":"158","author":"Stoffel","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1053\/j.gastro.2020.12.036","article-title":"Prognostic Factors for Advanced Colorectal Neoplasia in Inflammatory Bowel Disease: Systematic Review and Meta-analysis","volume":"160","author":"Wijnands","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/978-1-4939-3603-8_26","article-title":"AOM\/DSS Model of Colitis-Associated Cancer","volume":"Volume 1422","author":"Parang","year":"2016","journal-title":"Gastrointestinal Physiology and Diseases"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00281-012-0352-6","article-title":"Inflammation and colorectal cancer: Colitis-associated neoplasia","volume":"35","author":"Grivennikov","year":"2013","journal-title":"Semin. Immunopathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/jgh.14872","article-title":"The epidemiology of inflammatory bowel disease: East meets west","volume":"35","author":"Mak","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"9872","DOI":"10.3748\/wjg.v20.i29.9872","article-title":"Colorectal cancer in inflammatory bowel disease: The risk, pathogenesis, prevention and diagnosis","volume":"20","author":"Kim","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJMra1403718","article-title":"Cancers complicating inflammatory bowel disease","volume":"372","author":"Beaugerie","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/cac2.12331","article-title":"p38\u03b3 and p38\u03b4 as biomarkers in the interplay of colon cancer and inflammatory bowel diseases","volume":"42","author":"Fajardo","year":"2022","journal-title":"Cancer Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: A changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12957-020-01817-8","article-title":"CDK1 and CDC20 overexpression in patients with colorectal cancer are associated with poor prognosis: Evidence from integrated bioinformatics analysis","volume":"18","author":"Li","year":"2020","journal-title":"World J. Surg. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cmet.2016.07.015","article-title":"Iron Uptake via DMT1 Integrates Cell Cycle with JAK-STAT3 Signaling to Promote Colorectal Tumorigenesis","volume":"24","author":"Xue","year":"2016","journal-title":"Cell Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cell.2007.12.018","article-title":"Autophagy in the pathogenesis of disease","volume":"132","author":"Levine","year":"2008","journal-title":"Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.cell.2016.05.051","article-title":"Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment","volume":"166","author":"Zhong","year":"2016","journal-title":"Cell"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Sakitani, K., Hirata, Y., Hikiba, Y., Hayakawa, Y., Ihara, S., Suzuki, H., Suzuki, N., Serizawa, T., Kinoshita, H., and Sakamoto, K. (2015). Inhibition of autophagy exerts anti-colon cancer effects via apoptosis induced by p53 activation and ER stress. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1789-5"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41392-018-0031-8","article-title":"The role of autophagy in colitis-associated colorectal cancer","volume":"3","author":"Wu","year":"2018","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1747-1028-5-14","article-title":"Stat3: Linking inflammation to epithelial cancer\u2014More than a \u201cgut\u201d feeling?","volume":"5","author":"Jarnicki","year":"2010","journal-title":"Cell Div."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cyto.2009.07.365","article-title":"Linking inflammation to cancer\u2013A novel role for Stat3","volume":"1","author":"Ernst","year":"2009","journal-title":"Cytokine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1096\/fj.05-4331fje","article-title":"Sphingosine kinase 1 is up-regulated in colon carcinogenesis","volume":"20","author":"Kawamori","year":"2006","journal-title":"FASEB J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"10279","DOI":"10.3748\/wjg.v20.i30.10279","article-title":"STAT3 and sphingosine-1-phosphate in inflammation-associated colorectal cancer","volume":"20","author":"Nguyen","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/nature09128","article-title":"Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2","volume":"465","author":"Alvarez","year":"2010","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1089\/scd.2008.0063","article-title":"Sphingosine-1-Phosphate mediates transcriptional regulation of key targets associated with survival, proliferation, and pluripotency in human embryonic stem cells","volume":"17","author":"Avery","year":"2008","journal-title":"Stem Cells Dev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S0163-7827(03)00015-8","article-title":"Pleiotropic actions of sphingosine-1-phosphate","volume":"42","author":"Watterson","year":"2003","journal-title":"Prog. Lipid Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1096\/fj.08-117572","article-title":"Role for sphingosine kinase 1 in colon carcinogenesis","volume":"23","author":"Kawamori","year":"2009","journal-title":"FASEB J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7211","DOI":"10.1128\/MCB.02341-05","article-title":"Intracellular role for Sphingosine Kinase 1 in intestinal adenoma cell proliferation","volume":"26","author":"Kohno","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Matsuoka, K., and Hibi, T. (2023). Etrasimod for ulcerative colitis: Evaluating phase III results. Nat. Rev. Gastroenterol. Hepatol., Erratum in Nat. Rev. Gastroenterol. Hepatol. 2023.","DOI":"10.1038\/s41575-023-00793-0"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): Two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10495-013-0933-4","article-title":"Regulation of inflammation by DAPK","volume":"19","author":"Lai","year":"2014","journal-title":"Apoptosis"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0002-9440(10)63511-0","article-title":"Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation","volume":"163","author":"Kang","year":"2003","journal-title":"Am. J. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.prp.2010.05.004","article-title":"Aberrant methylation of DAPK in long-standing ulcerative colitis and ulcerative colitis-associated carcinoma","volume":"206","author":"Kuester","year":"2010","journal-title":"Pathol.-Res. Pract."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1053\/j.gastro.2013.04.011","article-title":"TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis","volume":"145","author":"Su","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jcmgh.2014.11.006","article-title":"Mechanisms of immune signaling in colitis-associated cancer","volume":"1","author":"Waldner","year":"2014","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Suzuki, M., Nagaishi, T., Yamazaki, M., Onizawa, M., Watabe, T., Sakamaki, Y., Ichinose, S., Totsuka, M., Oshima, S., and Okamoto, R. (2014). Myosin light chain kinase expression induced via tumor necrosis factor receptor 2 signaling in the epithelial cells regulates the development of colitis-associated carcinogenesis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0088369"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Janani, B., Vijayakumar, M., Priya, K., Kim, J.H., Prabakaran, D.S., Shahid, M., Al-Ghamdi, S., Alsaidan, M., Bahakim, N.O., and Abdelzaher, M.H. (2022). EGFR-Based targeted therapy for colorectal cancer\u2014Promises and challenges. Vaccines, 10.","DOI":"10.3390\/vaccines10040499"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/annonc\/mdi057","article-title":"Epidermal growth factor receptor signaling in colorectal cancer: Preclinical data and therapeutic perspectives","volume":"16","author":"Spano","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1440-1746.2011.06909.x","article-title":"Mucins in inflammatory bowel diseases and colorectal cancer","volume":"27","author":"Sheng","year":"2012","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Testa, U., Pelosi, E., and Castelli, G. (2018). Colorectal cancer: Genetic Abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells. Med. Sci., 6.","DOI":"10.3390\/medsci6020031"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.biopha.2014.09.006","article-title":"Upregulation of MAPK\/Erk and PI3K\/Akt pathways in ulcerative colitis-associated colon cancer","volume":"68","author":"Setia","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nri1153","article-title":"Class II cytokine receptors and their ligands: Key antiviral and inflammatory modulators","volume":"3","author":"Renauld","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1136\/gutjnl-2019-318448","article-title":"JAK selectivity for inflammatory bowel disease treatment: Does it clinically matter?","volume":"68","author":"Danese","year":"2019","journal-title":"Gut"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e27080","DOI":"10.4161\/jkst.27080","article-title":"STATs get their move on","volume":"2","author":"Reich","year":"2013","journal-title":"JAK-STAT"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1126\/science.8197455","article-title":"Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins","volume":"264","author":"Darnell","year":"1994","journal-title":"Science"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMct1209614","article-title":"Tumor necrosis factor inhibitors for inflammatory bowel disease","volume":"369","author":"Nielsen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.tips.2016.10.014","article-title":"Novel targeted therapies for inflammatory bowel disease","volume":"38","author":"Coskun","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn\u2019s disease: Results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"Panaccione","year":"2022","journal-title":"Lancet"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: Results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.pharmthera.2018.07.003","article-title":"Targeting JAK-STAT signal transduction in IBD","volume":"192","author":"Soendergaard","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.molmed.2017.02.002","article-title":"Sphingosine-1-Phosphate Signaling in Inflammatory Bowel Disease","volume":"23","author":"Nielsen","year":"2017","journal-title":"Trends Mol. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1056\/NEJMra1909094","article-title":"Reframing immune-mediated inflammatory diseases through signature cytokine hubs","volume":"385","author":"Schett","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_50","first-page":"14","article-title":"Janus Kinase inhibitors for the management of patients with inflammatory bowel disease","volume":"18","author":"Sedano","year":"2022","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.cgh.2014.01.029","article-title":"A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn\u2019s disease","volume":"12","author":"Sandborn","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus Kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: A systematic review and meta-analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-020-0954-2","article-title":"Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis","volume":"35","author":"Talpaz","year":"2021","journal-title":"Leukemia"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/art.41316","article-title":"Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3\/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate","volume":"72","author":"Robinson","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"ii24","DOI":"10.1093\/rheumatology\/keaa895","article-title":"The safety of JAK-1 inhibitors","volume":"60","author":"Clarke","year":"2021","journal-title":"Rheumatology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00575-5","article-title":"JAK inhibitors and VTE risk: How concerned should we be?","volume":"17","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/apt.16785","article-title":"Review article: Emerging drug therapies in inflammatory bowel disease","volume":"55","author":"Grossberg","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"108402","DOI":"10.1016\/j.pharmthera.2023.108402","article-title":"Selective JAK1 inhibitors for the treatment of inflammatory bowel disease","volume":"245","author":"Nielsen","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ecco-jcc\/jjab206","article-title":"Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis","volume":"16","author":"Magro","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1007\/s12325-022-02168-4","article-title":"MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases","volume":"39","author":"Hellstrom","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.tips.2022.02.008","article-title":"Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease","volume":"43","author":"Nielsen","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients with Crohn\u2019s Disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: Results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): A phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): Results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"ref_67","unstructured":"Tirumalaraju, D. (2023, June 28). Theravance\u2019s Izencitinib Fails in Phase IIb Ulcerative Colitis Trial. Clinical Trials Arena. Available online: https:\/\/www.clinicaltrialsarena.com\/news\/theravance-izencitinib-ulcerative-colitis\/?cf-view&cf-closed."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/ecco-jcc\/jjaa049","article-title":"Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme","volume":"14","author":"Sandborn","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","article-title":"Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo [3.2.1]octan-8-yl)methanone (PF-06700841)","volume":"61","author":"Fensome","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.cgh.2022.12.029","article-title":"Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results from a Randomized, Phase 2b Study","volume":"21","author":"Sandborn","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/annrheumdis-2021-221051","article-title":"Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years","volume":"81","author":"Winthrop","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_72","first-page":"1432","article-title":"Herpes zoster and Janus kinase inhibition in rheumatology and gastroenterology patients: Managing risk and vaccination","volume":"40","author":"Galloway","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.3389\/fimmu.2019.01862","article-title":"Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases","volume":"10","author":"Szilveszter","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40265-020-01346-4","article-title":"Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review","volume":"80","author":"Gisbert","year":"2020","journal-title":"Drugs"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Gargalionis, A.N., Papavassiliou, K.A., and Papavassiliou, A.G. (2021). Targeting STAT3 Signaling Pathway in Colorectal Cancer. Biomedicines, 9.","DOI":"10.3390\/biomedicines9081016"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/11\/1620\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:18:06Z","timestamp":1760131086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/11\/1620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,6]]},"references-count":76,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["biom13111620"],"URL":"https:\/\/doi.org\/10.3390\/biom13111620","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,6]]}}}